Colorectal cancer's notorious resistance to immunotherapy has long frustrated clinicians, but a newly characterized molecular switch may explain why checkpoint inhibitors fail in so many patients — and point toward a more precise way to disable tumor immune defenses simultaneously on two fronts.
Researchers working with patient-derived organoids, xenograft models, and mouse genetic knockouts identified that the enzyme ZDHHC5 palmitoylates β-catenin at a single cysteine residue (C466), and this lipid modification functions as a competitive switch that displaces an opposing modification called S-nitrosylation. The palmitoylated β-catenin then stabilizes its complex with the transcription factor TCF4, which in turn drives expression of two immunosuppressive targets in parallel: SLC7A11, a cystine transporter that blocks immunogenic ferroptosis — a form of oxidative cell death that normally primes CD8+ T cells — and PD-L1, which directly suppresses cytotoxic T-cell activity. The net effect is a coordinated shutdown of both the initiation and the effector phases of anti-tumor immunity. Importantly, ZDHHC5 expression in patient tumor samples correlated with poor survival and resistance to anti-PD-L1 therapy. A first-in-class small molecule inhibitor, β-cat-oxazole, was shown to disrupt the ZDHHC5–β-catenin interaction, restoring ferroptotic signaling and reducing PD-L1-driven immunosuppression.
This work is notable for mechanistically linking lipid post-translational modification to immune evasion in a clinically actionable way. Prior research had established that Wnt/β-catenin signaling suppresses tumor immunity and correlates with checkpoint therapy resistance, but the upstream palmitoylation event at C466 as a druggable node is a genuinely novel mechanistic layer. The dual-pathway suppression model — simultaneously blocking T-cell priming via ferroptosis inhibition and dampening effector T-cell killing via PD-L1 — provides a coherent explanation for why single-agent checkpoint blockade underperforms in Wnt-high colorectal cancers. Key limitations include the absence of fully immunocompetent human clinical data and the early-stage nature of β-cat-oxazole as a pharmacological tool. Still, this finding is more than incremental: it identifies a single enzymatic target whose inhibition may reactivate two complementary arms of anti-tumor immunity, making it a compelling candidate for combination immunotherapy strategies.